NCT03570203 is a clinical trial of Serum Sodium in Supratentorial Brain Tumor, sponsored by National Institute of Mental Health and Neuro Sciences, India.

Who is sponsoring NCT03570203?

NCT03570203 is sponsored by National Institute of Mental Health and Neuro Sciences, India.

What drugs are being tested in NCT03570203?

Interventions in NCT03570203: Serum Sodium.

What condition does NCT03570203 study?

NCT03570203 studies Supratentorial Brain Tumor.

Is NCT03570203 still recruiting?

NCT03570203 is currently completed. Last updated 26 June 2018.

Last reviewed 2018-06-26 · How we verify

NCT03570203

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Spectrum of Serum Sodium Disturbances in Patients With Non-sellar/Suprasellar Supratentorial Tumors

Completed Last updated 26 June 2018

What this trial tests

trial testing Serum Sodium in Supratentorial Brain Tumor in 173 participants. Completed in 30 April 2014.

Timeline

15 December 2013

Primary endpoint
30 April 2014

30 April 2014

Quick facts

Lead sponsor	National Institute of Mental Health and Neuro Sciences, India
Status	Completed
Study type	OBSERVATIONAL
Enrollment	173
Start date	15 December 2013
Primary completion	30 April 2014
Estimated completion	30 April 2014

Drugs / interventions tested

Serum Sodium

Conditions studied

Supratentorial Brain Tumor — all drugs for Supratentorial Brain Tumor →

Sponsor

National Institute of Mental Health and Neuro Sciences, India

Who can join

18 and older, any sex, with Supratentorial Brain Tumor. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study was designed to quantify the incidence of hyponatremia in patients of supratentorial/supra-sellar lesions and observe their effect on neurological morbidity and mortality.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other National Institute of Mental Health and Neuro Sciences, India trials

Trials by the same sponsor.

NCT04629352 — Effect of Neuroplasticity Modulation in tDCS Treatment Response Among Schizophrenia Patients With Auditory Hallucination · NA · recruiting
NCT05230641 — Cardiac Autonomic Dysfunction and Perioperative Outcomes · completed
NCT05264012 — Incidence, Risk Factors and Impact of Significant Pain in Patients Undergoing Neurosurgery · completed
NCT05189561 — Near-infrared Spectroscopy (NIRS) for Intracranial Hematoma Detection · NA · completed
NCT04630119 — Prospective Analysis of Quality of Life, Presenteeism, and Emotional Health Due to Chronic Neck Pain in Homemakers · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03570203 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by National Institute of Mental Health and Neuro Sciences, India
Last refreshed: 26 June 2018

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03570203.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing